The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study.
M. M. Heiss
Consultant or Advisory Role - Fresenius Biotech; TRION Pharma
Research Funding - Fresenius Biotech; TRION Pharma
M. A. Ströhlein
Consultant or Advisory Role - Fresenius Biotech; TRION Pharma
Research Funding - Fresenius Biotech; TRION Pharma
C. Bokemeyer
Consultant or Advisory Role - Fresenius Biotech (U)
Honoraria - Fresenius Biotech
Research Funding - Fresenius Biotech
D. Arnold
Consultant or Advisory Role - Fresenius Biotech (U)
Research Funding - Fresenius Biotech
S. L. Parsons
Consultant or Advisory Role - Fresenius Biotech (U)
M. G. Ott
Employment or Leadership Position - Fresenius Biotech
E. Schulze
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
H. Lindhofer
Employment or Leadership Position - TRION Pharma
Stock Ownership - TRION Pharma
D. Seimetz
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech (B)
M. Hennig
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech